Alkermes Flags Increased Trial Supply Costs from 31 July 2026 US Tariffs
Alkermes faces increased clinical trial supply expenses due to complex customs valuation requirements and varied VAT treatments across jurisdictions. Upcoming US tariff adjustments from 31 July 2026 will impose differential duties on blinded versus unblinded trial materials, compelling higher operational costs unless mitigated through early trade compliance measures.
1. Customs Valuation Challenges
Clinical trial products lack a market price, requiring customs valuation based on API costs, manufacturing contracts, packaging, labeling and yield. Blinded studies often use elevated invoice values to preserve trial blindness, leading to higher VAT and import taxes across multiple jurisdictions with distinct procedures.
2. Geopolitical Risks and Fuel Costs
Regional conflicts such as the Iran war and the Strait of Hormuz closure can raise fuel prices and marginally increase transportation expenses. Unless shipping routes cross active conflict zones, distribution timelines remain stable, though companies must monitor potential cost fluctuations.
3. Upcoming US Pharma Tariff Changes
Starting 31 July 2026, US pharma tariff waivers for clinical trial materials will be reduced, introducing differential duty rates for blinded versus unblinded products. Eligible trial imports may still utilize Chapter 98 waivers, while export activities remain free of reciprocal duty increases.
4. Trade Compliance Recommendations
Proactive, country-by-country planning with detailed customs rationales and early involvement of trade compliance teams or external consultants can prevent delays and tax overpayments. Preparing compliant invoices and engaging expertise before trial initiation is essential to control supply costs.